UPC Analytics
ENDE
Overview · Filed: Jan 5, 2026

UPC_CFI_29/2026

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

InfringementMain Infringement ActionBrussels LDInfringementWritten Phase
OverviewDecisionsDocumentsTimeline
Parties

Claimants

  • 2seventy bio, Inc.

Respondents

  • Johnson & Johnson
  • Janssen Biotech, Inc.
  • Janssen Pharmaceuticals Inc.
  • Janssen-Cilag International NV
  • Janssen Pharmaceutica NV
  • Janssen-Cilag NV
  • Janssen Biologics B.V.
  • Janssen-Cilag B.V.
  • Janssen-Cilag GmbH
  • Janssen-Cilag
  • Janssen-Cilag SpA
  • Janssen-Cilag A/S
  • Janssen-Cilag Aktiebolag
  • Janssen-Cilag Farmaceutica Lda.
  • Legend Biotech Corporation
  • Legend Biotech USA Inc.
  • Legend Biotech Ireland Limited
  • Legend Biotech Belgium BV
Judges
  • Samuel Granata
  • Marije Knijff
  • Anna Lena Klein
Patents
  • EP3689383
CPC codes: A61P35/00, C07K16/2878, A61K39/395, A61K2039/505, C07K2317/622, C07K14/70517, A61K40/31, C07K14/70503, A61K2121/00, A61K2300/00, A61P35/02, A61P43/00…

Technology area: Biotech · Cell Therapy

Sector: Biotechnology

Outcome
—
Filed: Jan 5, 2026
First decided: —
Language: English
Open on UPC Registry